Nantes, France and Chicago, IL — June 22, 2021 — InFlectis BioScience has been granted exclusive patent rights from the University of Chicago to use a family of small molecules for the treatment of demyelinating diseases. The license covers the use of InFlectis BioSciences’ lead compounds, IFB-088 and IFB-048, for the treatment of CMT and MS, two highly prevalent demyelinating diseases. IFB-088 is entering Phase 2 clinical trials for the treatment of ALS and CMT and has shown encouraging preclinical results for the treatment of multiple sclerosis (MS). These small molecules, known as ISR (Integrated Stress Response) modulators, are oral compounds that selectively prolong the body’s natural protective effect against cellular stress as a way to potentially delay or halt disease progression.
To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
- InFlectis BioScience has licensed rights from the University of Chicago for the use of a family of molecules to treat demyelinating diseases.
- The license covers the use of drugs that InFlectis BioScience is developing for the treatment of CMT as well as molecules in preclinical development for the treatment of MS.
- The compounds have been shown to prolong the ISR, the body’s protective response against cellular stress, offering a potential new approach to slow or halt disease progression.
Click image above to view full announcement.
Source: Inflectis
Distributed by: Reportable, Inc.
